Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 894416 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2018
At a glance
- Drugs BI 894416 (Primary) ; BI 894416 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Boehringer Ingelheim
- 11 Sep 2018 Status changed from active, no longer recruiting to completed.
- 25 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Jul 2018 Planned number of patients changed from 80 to 76.